Market Scoping
& Market Access
Overview
We apply our expertise in data science, epidemiology, and health economics and outcomes research (HEOR) to help our clients gain a clear understanding of the markets in which they intend to enter or expand. This includes market sizing and market share, but also dynamic factors, such as growth potential. Our knowledge of U.S. and global healthcare markets also supports preparation for market access globally, including strategic assessments of key market access opportunities and challenges, compiling of clinical and economic evidence, building economic models for regulatory submissions, and strategic engagement with health technology assessment (HTA) authorities.
Types Of Engagements
- Development of global value dossiers
- Preparing materials in advance of review by U.S. Institute for Clinical and Economic Review (ICER)
- Preparing materials in advance of submission to UK National Institute for Health and Care Excellence (NICE)
- Novel analysis of real-world data (RWD) to support HTA submissions
- Supporting submissions and responses to HTA reviews
- Survey research of payer key opinion leaders (KOLs)
- Global model adaptation
- Estimation of market size for medical devices, diagnostics, & pharmaceuticals
- Systematic & comprehensive summaries of literature & evidence
- Publications in peer-reviewed journals
Key Staff
- Andrew Briggs, DPhil, MSc
- John Schneider, PhD
- Jacie Cooper, MS
- Anthony LoSasso, PhD
- Robert Ohsfeldt, PhD
Related Markets & Industries
- Insurance & Third-Party Payers
- Medical Services
- Hospitals & Health Systems
- Pharmaceuticals & Biotechnology
- Medical Devices & Diagnostics
- Private Equity & Venture Capital
- Consumer Products
- Public Health
- Government
Related Publications
- Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation. 2022
- Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. 2022
- Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies. 2021
- Reimbursement for genetic variant reinterpretation: five questions payers should ask. 2021
- Count the cost of disability caused by COVID-19. 2021
- Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. 2021
- An Attribution of Value Framework for Combination Therapies: Report by the Value Attribution Working Group. 2021
- Genetic Variant Reinterpretation: Economic and Population Health Management Challenges. 2021
- A Cost-Offset Analysis of the Roxadustat Incident Dialysis-Dependent Global Phase 3 Program: A US Healthcare Perspective. 2021
- A Cost-Offset Analysis of the Roxadustat Incident Dialysis-Dependent Global Phase 3 Program: A Canadian Healthcare Perspective. 2021
- Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections. 2020
- Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. 2020
- 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. 2019
- Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. 2019
- A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. 2019
- Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study 2017
- Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. 2017
- Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer 2016
- A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. 2015
- Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks? 2015
- Projecting long-term graft and patient survival after transplantation. 2014
- Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference ELicitation in TriAls (DELTA) Systematic Review. 2014
- Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. 2014
- Population ageing and healthcare expenditure projections: new evidence from a time to death approach. 2013
- International comparison of comparative effectiveness research in five jurisdictions: insights for the US. 2010
Related Issue Briefs
- Economic Evaluation and Market Access for Medical Devices in the U.S.: Implications of a U.S. Health Technology Assessment Agency (Issue Brief No. 53)
- Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma (Issue Brief No. 47)
- How Important is ICER Preparation and Review for U.S. Market Access? (Issue Brief No. 43)
- Using Payer Research to Assess Medical Device Market Access (Issue Brief No. 42)
- Smoke, Mirrors, and Wild Geese: What Should Be the Future Directions of HEOR in the 2020s? (Issue Brief No. 40)
- The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research (Issue Brief No. 37)
- Value-Based Payment for Oncology Services (Issue Brief No. 34)
- Why Medical Device Companies Need to Develop Economic Evidence in the U.S. (Issue Brief No. 33)
- Reference Pricing for in vivo and in vitro Diagnostic Tests (Issue Brief No. 32)
- Purchasing Medical Innovation: The Implications for the Medical Device Industry (Issue Brief No. 31)
- The New Era of Cost Control in Healthcare: What Should you look for in a Health Economics and Outcomes Research Consultant? (Issue Brief No. 27)
- Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs (Issue Brief No. 26)
- Health Care Costs and Value: An International Perspective (Issue Brief No.6)
- The Declining Health of the Local Market: When and How Should Your Health Care Business Expand into New Markets (Issue Brief No. 3)